$EKSO
EKSO BIONICS HOLDINGS, INC.

2016 Q4 Form 10-Q Financial Statement

#000114420416132829 Filed on November 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q3
Revenue $2.587M $1.596M $2.915M
YoY Change 33.14% -45.25% 83.56%
Cost Of Revenue $1.740M $1.193M $2.447M
YoY Change -18.69% -51.25% 120.85%
Gross Profit $843.0K $403.0K $468.0K
YoY Change -534.54% -13.89% -2.5%
Gross Profit Margin 32.59% 25.25% 16.05%
Selling, General & Admin $5.430M $5.053M $3.936M
YoY Change 22.85% 28.38% 26.32%
% of Gross Profit 644.13% 1253.85% 841.03%
Research & Development $2.290M $2.216M $1.713M
YoY Change 12.25% 29.36% 56.3%
% of Gross Profit 271.65% 549.88% 366.03%
Depreciation & Amortization $480.0K $470.0K $230.0K
YoY Change 71.43% 104.35% 9.52%
% of Gross Profit 56.94% 116.63% 49.15%
Operating Expenses $7.530M $7.269M $5.649M
YoY Change 16.56% 28.68% 34.12%
Operating Profit -$6.687M -$6.866M -$5.181M
YoY Change 0.5% 32.52% 38.83%
Interest Expense $20.00K $8.000K $4.000K
YoY Change 100.0% 33.33%
% of Operating Profit
Other Income/Expense, Net $1.090M -$1.612M -$2.000K
YoY Change -45.77% 80500.0% -86.67%
Pretax Income -$5.580M -$8.480M -$5.190M
YoY Change 20.0% 63.39% -143.18%
Income Tax
% Of Pretax Income
Net Earnings -$5.576M -$8.478M -$5.185M
YoY Change 20.04% 63.51% -143.12%
Net Earnings / Revenue -215.54% -531.2% -177.87%
Basic Earnings Per Share -$0.29 -$0.60 -$0.35
Diluted Earnings Per Share -$0.35 -$0.60 -$0.35
COMMON SHARES
Basic Shares Outstanding 21.88M shares 19.01M shares 14.61M shares
Diluted Shares Outstanding 19.01M shares 14.61M shares

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.85M $12.80M $11.24M
YoY Change -13.81% 13.88% 56.55%
Cash & Equivalents $16.85M $11.24M
Short-Term Investments
Other Short-Term Assets $500.0K $620.0K $2.650M
YoY Change -80.24% -76.6% 55.88%
Inventory $1.556M $1.920M $1.179M
Prepaid Expenses
Receivables $1.780M $2.200M $2.185M
Other Receivables $0.00 $30.00K $0.00
Total Short-Term Assets $20.68M $17.57M $17.25M
YoY Change -17.92% 1.87% 47.9%
LONG-TERM ASSETS
Property, Plant & Equipment $2.435M $2.560M $2.399M
YoY Change -7.24% 6.71% 22.57%
Goodwill $189.0K $189.0K
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $91.00K $90.00K $55.00K
YoY Change -6.19% 63.64% 0.43%
Total Long-Term Assets $3.741M $4.050M $4.878M
YoY Change -46.53% -16.97% 29.87%
TOTAL ASSETS
Total Short-Term Assets $20.68M $17.57M $17.25M
Total Long-Term Assets $3.741M $4.050M $4.878M
Total Assets $24.43M $21.62M $22.13M
YoY Change -24.14% -2.29% 43.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.374M $1.360M $2.148M
YoY Change -11.88% -36.69% 99.43%
Accrued Expenses $3.130M $2.310M $2.190M
YoY Change 66.05% 5.48% 65.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $50.00K $70.00K $80.00K
YoY Change -37.5% -12.5% 100.0%
Total Short-Term Liabilities $6.314M $5.510M $8.256M
YoY Change -26.74% -33.26% 40.03%
LONG-TERM LIABILITIES
Long-Term Debt $6.790M $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $107.0K $7.890M $4.620M
YoY Change -45.13% 70.78% -69.92%
Total Long-Term Liabilities $107.0K $7.890M $4.620M
YoY Change -45.13% 70.78% -70.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.314M $5.510M $8.256M
Total Long-Term Liabilities $107.0K $7.890M $4.620M
Total Liabilities $17.89M $13.39M $12.88M
YoY Change -23.5% 3.96% -39.64%
SHAREHOLDERS EQUITY
Retained Earnings -$114.9M -$109.3M -$86.75M
YoY Change 25.68% 25.98% 67.96%
Common Stock $22.00K $21.00K $102.0K
YoY Change 46.67% -79.41% 29.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.531M $8.228M $9.246M
YoY Change
Total Liabilities & Shareholders Equity $24.43M $21.62M $22.13M
YoY Change -24.14% -2.28% 43.51%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$5.576M -$8.478M -$5.185M
YoY Change 20.04% 63.51% -143.12%
Depreciation, Depletion And Amortization $480.0K $470.0K $230.0K
YoY Change 71.43% 104.35% 9.52%
Cash From Operating Activities -$4.440M -$6.440M -$4.620M
YoY Change -14.45% 39.39% 28.69%
INVESTING ACTIVITIES
Capital Expenditures -$370.0K -$130.0K -$400.0K
YoY Change -30.19% -67.5% 60.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$370.0K -$130.0K -$400.0K
YoY Change -30.19% -67.5% 66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.770M 14.71M 10.00K
YoY Change -37.49% 147000.0% -75.0%
NET CHANGE
Cash From Operating Activities -4.440M -6.440M -4.620M
Cash From Investing Activities -370.0K -130.0K -400.0K
Cash From Financing Activities 8.770M 14.71M 10.00K
Net Change In Cash 3.960M 8.140M -5.010M
YoY Change -52.35% -262.48% 32.19%
FREE CASH FLOW
Cash From Operating Activities -$4.440M -$6.440M -$4.620M
Capital Expenditures -$370.0K -$130.0K -$400.0K
Free Cash Flow -$4.070M -$6.310M -$4.220M
YoY Change -12.66% 49.53% 26.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1000 USD
CY2016Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
101000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28239000 USD
CY2016Q3 us-gaap Sales Revenue Net
SalesRevenueNet
1596000 USD
CY2015Q3 us-gaap Cost Of Services
CostOfServices
1352000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
10345000 USD
CY2016Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
117498000 USD
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
100184000 USD
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109284000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91390000 USD
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
8228000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
8808000 USD
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21621000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32198000 USD
CY2016Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
768000 USD
CY2015Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
768000 USD
CY2016Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
21000 USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
15000 USD
CY2016Q3 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
34000 USD
CY2015Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
0 USD
CY2016Q3 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
41000 USD
CY2015Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
0 USD
CY2016Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7000 USD
us-gaap Net Income Loss
NetIncomeLoss
-17894000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-20000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-36000 USD
CY2015Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
1820000 USD
CY2015Q3 us-gaap Sales Revenue Net
SalesRevenueNet
2915000 USD
CY2016Q3 us-gaap Cost Of Services
CostOfServices
70000 USD
CY2016Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1193000 USD
CY2015Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2447000 USD
CY2016Q3 us-gaap Gross Profit
GrossProfit
403000 USD
CY2016Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2735000 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2216000 USD
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1713000 USD
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2318000 USD
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
7269000 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6866000 USD
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1612000 USD
CY2016Q3 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
1162000 USD
CY2015Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
1584000 USD
CY2016Q3 us-gaap Goodwill
Goodwill
189000 USD
CY2015Q4 us-gaap Goodwill
Goodwill
189000 USD
CY2016Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
6165000 USD
CY2015Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
9195000 USD
us-gaap Cost Of Services
CostOfServices
452000 USD
us-gaap Cost Of Services
CostOfServices
2482000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9530000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5345000 USD
us-gaap Gross Profit
GrossProfit
2104000 USD
us-gaap Gross Profit
GrossProfit
1373000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8151000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6754000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4438000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-20904000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3010000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-36000 USD
us-gaap Net Income Loss
NetIncomeLoss
-14945000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14945000 USD
ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
0 USD
CY2015Q3 us-gaap Gross Profit
GrossProfit
468000 USD
CY2015Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2380000 USD
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1556000 USD
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
5649000 USD
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5181000 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-8478000 USD
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11494000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
131000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
636000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1026000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
94000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
338000 USD
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-4498000 USD
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
776000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1335000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1365000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1279000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-188000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6653000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
931000 USD
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-5185000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
40000 USD
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000 USD
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0 USD
CY2016Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
3016000 USD
CY2015Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5185000 USD
CY2016Q3 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
-1620000 USD
CY2015Q3 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
0 USD
CY2016Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8000 USD
CY2015Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-4000 USD
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11511000 USD
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5185000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28245000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14945000 USD
CY2016Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-17000 USD
CY2015Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-6000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 USD
us-gaap Depreciation
Depreciation
1381000 USD
us-gaap Depreciation
Depreciation
653000 USD
us-gaap Amortization Of Deferred Charges
AmortizationOfDeferredCharges
-27000 USD
us-gaap Amortization Of Deferred Charges
AmortizationOfDeferredCharges
-28000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2552000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1259000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
379000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-20555000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13082000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
728000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
962000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-728000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-962000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6752000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-13952000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25190000 USD
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11238000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
58000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
14537000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
92000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
173000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
52000 USD
us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
75000 USD
us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
0 USD
us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-6000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-6000 USD
CY2016Q3 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
92000 USD
CY2015Q4 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
4590000 USD
CY2016Q3 us-gaap Deferred Rent Credit
DeferredRentCredit
74000 USD
CY2015Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
71000 USD
CY2016Q3 us-gaap Deferred Revenue
DeferredRevenue
1920000 USD
CY2015Q4 us-gaap Deferred Revenue
DeferredRevenue
8573000 USD
CY2016Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
135000 USD
CY2016Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
537000 USD
CY2016Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
490000 USD
CY2016Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1988000 USD
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1464000 USD
CY2016Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
137000 USD
ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
3030000 USD
CY2016Q3 ekso Product Maintenance Warranty Liabilities Current Noncurrent
ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent
774000 USD
us-gaap Cost Of Property Repairs And Maintenance
CostOfPropertyRepairsAndMaintenance
911000 USD
CY2016Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
179000 USD
CY2016Q3 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
13000 USD
CY2016Q3 us-gaap Capital Lease Obligations
CapitalLeaseObligations
166000 USD
CY2016Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
99000 USD
CY2016Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
23000 USD
CY2016Q3 us-gaap Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Two
LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo
60000 USD
CY2016Q3 us-gaap Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Three
LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree
37000 USD
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
257000 USD
CY2016Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
186000 USD
CY2015Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
0 USD
CY2016Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
92000 USD
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
164000 USD
CY2015Q4 ekso Accrued Maintenance Current
AccruedMaintenanceCurrent
0 USD
CY2016Q3 ekso Accrued Maintenance Current
AccruedMaintenanceCurrent
579000 USD
CY2015Q4 ekso Product Maintenance Warranty Liabilities Current Noncurrent
ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent
0 USD
ekso Product Maintenance Warranty Addition
ProductMaintenanceWarrantyAddition
1267000 USD
ekso Product Maintenance Warranty Expense
ProductMaintenanceWarrantyExpense
493000 USD
CY2016Q3 ekso Product Maintenance Warranty Liabilities Current
ProductMaintenanceWarrantyLiabilitiesCurrent
765000 USD
CY2016Q3 ekso Product Maintenance Warranty Liabilities Noncurrent
ProductMaintenanceWarrantyLiabilitiesNoncurrent
9000 USD
CY2016Q3 us-gaap Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Four
LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour
37000 USD
CY2016Q3 us-gaap Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Five
LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive
22000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
299000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
258000 USD
CY2016Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
101000 USD
CY2015Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
86000 USD
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6559000 shares
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3795000 shares
ekso Reduction In Net Loss Attributable To Common Stock Holders
ReductionInNetLossAttributableToCommonStockHolders
2358000 USD
ekso Reduction In Net Loss Per Share Attributable To Common Stock Holders
ReductionInNetLossPerShareAttributableToCommonStockHolders
0.14
CY2016Q3 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
50000 USD
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
13000 shares
CY2015 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
15000 shares
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
71429000 shares
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21393000 shares
CY2015Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
9195000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3030000 USD
CY2016Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1620000 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
EKSO BIONICS HOLDINGS, INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001549084
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Trading Symbol
TradingSymbol
EKSO
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21880959 shares
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
13000 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
71429000 shares
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21393000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15027000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15027000 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1495000 USD
CY2015Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1095000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
11003000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
3128000 USD
CY2016Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1123000 USD
CY2015Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1095000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
9078000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
2863000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of the associated costs, future warranty costs, maintenance and planned improvement costs associated with medical device units sold prior to 2016, useful lives assigned to long-lived assets, realizability of deferred tax assets, the valuation of options and warrants, and contingencies. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Concentration of Credit Risk and Other Risks and Uncertainties</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. We maintain our cash accounts in excess of federally insured limits. However, we believe we are not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. &#160;We extend credit to customers in the normal course of business and perform ongoing credit evaluations of our customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. We do not require collateral from our customers to secure accounts receivable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Accounts receivable are derived from the sale of products shipped and services performed for customers located in the U.S. and throughout the world. Invoices are aged based on contractual terms with the customer. We review accounts receivable for collectability and provide an allowance for credit losses, as needed. We have not experienced any material losses related to accounts receivable as of September 30, 2016 and December 31, 2015. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We do not enter into any foreign currency hedging agreements and are susceptible to gains and losses from foreign currency fluctuations. To date, we have not experienced significant gains or losses upon settling foreign currency denominated accounts receivable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of September 30, 2016, we had one customer with an accounts receivable balance totaling <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% or more of our total accounts receivable (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13</font>%) compared with one customer as of December 31, 2015 (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font>%).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In the three months ended September 30, 2016, we had one customer with billed revenue of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% or more of total billed revenue (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font>%), compared with one customer in the three months ended September 30, 2015 (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">48</font>%). In the nine months ended September 30, 2016, we had no customers with sales comprising <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% or more of our total customer sales, compared with one customer in the nine months ended September 30, 2015 (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">33</font>%).</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
1380000 USD
CY2015Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
783000 USD
CY2016Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
432000 USD
CY2015Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
336000 USD
CY2016Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
151000 USD
CY2015Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
19000 USD
CY2016Q3 us-gaap Inventory Gross
InventoryGross
1963000 USD
CY2015Q4 us-gaap Inventory Gross
InventoryGross
1138000 USD
CY2016Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
48000 USD
CY2015Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
82000 USD
CY2016Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1610000 USD
CY2016Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
448000 USD
CY2016Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1162000 USD
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4085000 shares
CY2016Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4085000 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0125 pure
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0126 pure
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0168 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0124 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0141 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0178 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0250 pure
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8 pure
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.75 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.77 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.73 pure
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2552000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1259000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.75 pure
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
451000 USD
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
467000 USD
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14606000 shares
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19005000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17595000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14578000 shares
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19005000 shares
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14606000 shares
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-6000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
74000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
80000 USD
CY2016Q3 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
1000 shares
us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
10000 shares
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1389000 shares
CY2016Q3 ekso Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
7.07 pure
CY2011Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2017-05-31
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-7 reverse split
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14694000 USD
CY2016Q3 us-gaap Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal After Year Five
LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive
0 USD
CY2016Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-05-31
CY2016Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3000 shares
CY2016Q3 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
921000 shares
CY2016Q3 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
60000 shares
CY2016Q3 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
267 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16888000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14578000 shares
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.03
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.03
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4437000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3795000 shares
CY2016Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2015Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
707000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11494000 USD
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5185000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-31269000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14945000 USD
CY2016Q3 us-gaap Dilutive Securities
DilutiveSecurities
0 USD
CY2015Q3 us-gaap Dilutive Securities
DilutiveSecurities
0 USD
us-gaap Dilutive Securities
DilutiveSecurities
-3030000 USD
us-gaap Dilutive Securities
DilutiveSecurities
0 USD

Files In Submission

Name View Source Status
0001144204-16-132829-index-headers.html Edgar Link pending
0001144204-16-132829-index.html Edgar Link pending
0001144204-16-132829.txt Edgar Link pending
0001144204-16-132829-xbrl.zip Edgar Link pending
ekso-20160930.xml Edgar Link completed
ekso-20160930.xsd Edgar Link pending
ekso-20160930_cal.xml Edgar Link unprocessable
ekso-20160930_def.xml Edgar Link unprocessable
ekso-20160930_lab.xml Edgar Link unprocessable
ekso-20160930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pg4img1_ex10-38.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v451418_10q.htm Edgar Link pending
v451418_ex10-38.htm Edgar Link pending
v451418_ex31-1.htm Edgar Link pending
v451418_ex31-2.htm Edgar Link pending
v451418_ex32-1.htm Edgar Link pending
v451418_ex32-2.htm Edgar Link pending